Celgene Corp. gave an initial glimpse at sales for its recently launched Pomalyst (pomalidomide) to treat multiple myeloma, revealing early revenues that surpassed analyst expectations.
After FDA approved the drug Feb. 8, Pomalyst’s first-quarter sales were $29 million. Of that, $22 million was in the U.S., while $7 million came from early access programs in...